Tumor necrosis factor alpha, interleukin 2, and soluble interleukin 2 receptor levels in human immunodeficiency virus type 1-infected individuals receiving intermittent cycles of interleukin 2.

HIV-infected individuals with 200-500 CD4(+) T cell/microl were enrolled in a controlled study of three interleukin 2 (IL-2) plus antiretroviral therapy (ART) regimens: (1) continuous intravenous administration of 12 million international units (MIU) of IL-2 followed by subcutaneous high-dose IL-2 (7.5 MIU, twice daily) for 5 days every 8 weeks; (2) high-dose subcutaneous IL-2 for 5 days every 8 weeks; (3) low-dose (3 MIU, twice daily) subcutaneous IL-2 for 5 days every 4 weeks; and (4) ART alone. Serum concentrations of IL-2, soluble IL-2 receptor (sIL-2R), tumor necrosis factor alpha (TNF-alpha), and IL-6 were determined. A progressive decrease over time of the circulating levels of IL-2 was observed in individuals receiving the highest doses of IL-2, but not in those belonging to the low-dose arm. Conversely, increased levels of sIL-2R were observed in all cytokine-treated individuals. The levels of TNF-alpha increased in the high-dose IL-2 regimens, but decreased in individuals receiving low-dose IL-2. IL-2-related toxicity was significantly correlated to the peak IL-2 serum levels, and was substantially lower in those individuals receiving low-dose IL-2. In conclusion, intermittent IL-2 administration causes the elevation of peripheral CD4(+) T cells, but also a profound cytokine response and systemic toxicity. The latter was correlated to the peak serum level of IL-2, but not to those of TNF-alpha and IL-6.

[1]  C. Hallahan,et al.  CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients , 2001, AIDS.

[2]  A. Lazzarin,et al.  Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy. , 2001, The Journal of infectious diseases.

[3]  J. Thèze,et al.  Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment. , 2001, The Journal of infectious diseases.

[4]  M. Atkins,et al.  A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  G. Poli.  Cytokines and Chemokines in HIV Infection , 2001 .

[6]  R. Dewar,et al.  Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression. , 2000, The Journal of infectious diseases.

[7]  J. Kovacs,et al.  Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. , 2000, The Journal of infectious diseases.

[8]  J. Kahn,et al.  Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. , 2000, JAMA.

[9]  R. Davey,et al.  A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3. , 2000, The Journal of infectious diseases.

[10]  M. Caligiuri,et al.  Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. , 2000, The Journal of clinical investigation.

[11]  A. Lazzarin,et al.  In vivo administration of recombinant IL-2 to individuals infected by HIV down-modulates the binding and expression of the transcription factors ying-yang-1 and leader binding protein-1/late simian virus 40 factor. , 1999, Journal of immunology.

[12]  M. Juan,et al.  Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with , 1999, The Journal of infectious diseases.

[13]  É. Oksenhendler,et al.  Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial , 1999, The Lancet.

[14]  H. Tilg,et al.  Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy. , 1999, European cytokine network.

[15]  R. Dewar,et al.  A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. , 1999, The Journal of infectious diseases.

[16]  R. Detels,et al.  The prognostic significance in HIV infection of immune activation represented by cell surface antigen and plasma activation marker changes. , 1999, Clinical immunology.

[17]  J. Metcalf,et al.  Pharmacokinetic modeling of recombinant interleukin‐2 in patients with human immunodeficiency virus infection , 1998, Clinical pharmacology and therapeutics.

[18]  G. Stewart,et al.  Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group. , 1998, The Journal of infectious diseases.

[19]  A. Kelleher,et al.  Effects of IL‐2 therapy in asymptomatic HIV‐infected individuals on proliferative responses to mitogens, recall antigens and HIV‐related antigens , 1998, Clinical and experimental immunology.

[20]  Anthony S. Fauci,et al.  Induction of HIV-1 Replication in Latently Infected CD4+ T Cells Using a Combination of Cytokines , 1998, The Journal of experimental medicine.

[21]  A. Berger,et al.  Randomized, controlled phase II trial of subcutaneous interleukin‐2 in combination with highly active antiretroviral therapy (HAART) in HIV patients , 1998, AIDS.

[22]  M. Giacca,et al.  Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects. , 1997, The Journal of clinical investigation.

[23]  J. Metcalf,et al.  Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. , 1997, The Journal of infectious diseases.

[24]  J. Metcalf,et al.  Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. , 1996, The New England journal of medicine.

[25]  K. Smith,et al.  Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[27]  M. Caligiuri,et al.  Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. , 1995, Blood.

[28]  C. Fortis,et al.  Serum levels of soluble cell adhesion molecules (ICAM-1, VCAM-1, E-selectin) and of cytokine TNF-alpha increase during interleukin-2 therapy. , 1995, Clinical immunology and immunopathology.

[29]  J. Metcalf,et al.  Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. , 1995, The New England journal of medicine.

[30]  A. Fauci,et al.  HIV replication in IL-2-stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines. , 1995, Journal of immunology.

[31]  S. Barni,et al.  Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2. , 1991, European journal of cancer.

[32]  A. Barral,et al.  Toxic effects of interleukin-2-activated lymphocytes on vascular endothelial cells. , 1991, Natural immunity and cell growth regulation.

[33]  S. Kleinman,et al.  Interrelationships Between Serologic Markers of Immune Activation and T Lymphocyte Subsets in HIV Infection , 1990, Journal of acquired immune deficiency syndromes.

[34]  J. Justement,et al.  Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Kendall A. Smith,et al.  Interleukin-2: inception, impact, and implications. , 1988, Science.

[36]  J. Thompson,et al.  Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  S. Kleinman,et al.  Soluble IL-2 receptor levels in serum from blood donors seropositive for HIV. , 1988, Journal of immunology.

[38]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.

[39]  E. Gelmann,et al.  Use of interleukin-2 in patients with acquired immunodeficiency syndrome. , 1984, Journal of biological response modifiers.